Ryan Jason 4
4 · Singular Genomics Systems, Inc. · Filed Feb 25, 2025
Insider Transaction Report
Form 4
Ryan Jason
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−1,333→ 0 totalExercise: $672.90Exp: 2031-05-05→ Common Stock (1,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−1,541→ 0 totalExercise: $85.80Exp: 2032-05-26→ Common Stock (1,541 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21$8.84/sh−2,466$21,799→ 0 totalExercise: $11.16Exp: 2034-05-29→ Common Stock (2,466 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−2,466→ 0 totalExercise: $31.80Exp: 2033-05-25→ Common Stock (2,466 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, and after giving effect to the acceleration treatment set forth in footnote (2), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the amount of $20.00 per share over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
- [F2]As of the effective time of the merger contemplated within the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.